Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable G-protein coupled receptor 21 (GPR21) is an orphan class A G protein-coupled receptor implicated in the regulation of glucose metabolism and insulin responsiveness. It signals primarily through Gαq and Gαs proteins to influence pathways such as MAPK and cAMP accumulation, even in the absence of known endogenous ligands, due to a unique active conformation stabilized by its extracellular loop. GPR21 is widely expressed, particularly in the brain, immune tissues, and adipose tissue, and its dysregulation is associated with metabolic disorders such as type 2 diabetes and obesity, making it an emerging therapeutic target for these conditions
Modulation of Gαq and Gαs protein signaling pathways Alteration of cAMP production and MAPK cascades through receptor modulation Experimental drugs act as inverse agonists that reduce constitutive receptor activity and modulate insulin signaling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable G-protein coupled receptor 21 (GPR21).